IGMS Live signals | Maximize Profits with Getagraph.com

BUY 102448 min ago

@ $15.41

Issued: 14 Feb 2024 @ 13:56

Return: -50.36%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -4.82 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases...

Stats
Today's Volume	546 437
Average Volume	271 329
Market Cap	451.30M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.850 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.620
ATR14	$0.0300 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Harler Mary Beth	Sell	0	Common Stock
2024-04-14	Harler Mary Beth	Sell	200 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	75 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	52 500	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	92 500	Stock Option (right to buy)

INSIDER POWER
56.96
Last 99 transactions
Buy: 2 356 293 \| Sell: 614 616

Volume Correlation

Long: 0.21 (neutral)

Short: -0.61 (weak negative)

Signal:(81.82) Neutral

IGM Biosciences Inc Correlation

10 Most Positive Correlations
LWAC	0.811

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IGM Biosciences Inc Correlation - Currency/Commodity

-0.06
( neutral )

0.17
( neutral )

0.00
( neutral )

0.28
( neutral )

0.18
( neutral )

-0.29
( neutral )

IGM Biosciences Inc Financials

Annual	2023
Revenue:	$2.13M
Gross Profit:	$-6.15M (-288.59 %)
EPS:	$-4.71

Q4	2023
Revenue:	$651 000
Gross Profit:	$-1.53M (-235.02 %)
EPS:	$-1.010

Q3	2023
Revenue:	$509 000
Gross Profit:	$-1.75M (-343.81 %)
EPS:	$-1.040

Q2	2023
Revenue:	$448 000
Gross Profit:	$-3.07M (-685.27 %)
EPS:	$-1.430

Financial Reports:

No articles found.

IGM Biosciences Inc

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.